MannKind Corporation

NasdaqGM MNKD

MannKind Corporation Inventory for the quarter ending September 30, 2024

MannKind Corporation Inventory is NA for the quarter ending September 30, 2024. Inventory is the value of goods held by a company for sale or used in the production process.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

NasdaqGM: MNKD

MannKind Corporation

CEO	Dr. Michael E. Castagna Pharm.D.
IPO Date	July 28, 2004
Location	United States
Headquarters	30930 Russell Ranch Road
Employees	411
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Pet Food Snack Foods Vaccines

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Key trends

Past 5 years